

III. Amendments to the Specification

The title of the application has been replaced by a title more descriptive of the claimed subject matter and a cross-reference to the parent application has been added after the title. See attached pages 4-9.

IV. Amendments to the Claims

The amendments to claims 1 and 4 (use of type A toxin followed by use of type B toxin) are supported by at least Example 1 on page 13, and by original claims 2 and 5.

New claim 11 is supported by at least page 1, lines 24-25, page 5, lines 24, and example 2 on page 14-15 of the specification, all of which disclose treatment of cervical dystonia. Note that "cervical dystonia" and "spasmodic torticollis" are synonymous terms.

New claim 12 is supported since treatment of various dystonias, including cervical dystonia, oromandibular dystonia, laryngeal dystonia, lingual dystonia, focal dystonias, and tardive dystonia, is disclosed at at least page 1, lines 24-26, page 2, lines 11-12, and lines 17-18, and page 5, lines 23-35 of the specification.

New claims 13 and 17 are supported by at least page 1, lines 24-25, page 5, lines 24, and example 2 on page 14-15 of the specification, all of which disclose treatment of cervical dystonia.

New claims 14 and 18 are supported by at least Example 2 on pages 14-15 of the specification, which discloses treatment of the cervical dystonia symptom of "abnormal deviations of the head."

New claims 15 and 19 are supported since it was known in the art as of the effective filing date of this application (June 10, 1993) that treatment of cervical dystonia with a botulinum toxin type A can result in alleviation of the pain which accompanies cervical dystonia. See e.g. Jankovic J., et al., *Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy*, Adv Neurol 50(2);583-91:1988, and Jankovic J., *Botulinum toxin injections in patients with cervical dystonia*, Neurology 39(3) supp 1;294:1989. The abstracts of both these articles are attached.

New claim 16 is supported by at least original claims 4 and 5.


Thus, no new matter is introduced by any of the claim amendments or by any of the new claims.

V. Conclusion

Examination and allowance of the pending claims 1, 4 and 11-19 is requested.

Respectfully Submitted,

Date: March 15, 2001


Stephen Donovan
Registration Number 33,433

Please direct all correspondence to:

Stephen Donovan
Legal Department
Allergan, Inc. T2 7H
2525 Dupont Drive
Irvine, California 92612
Telephone: 714 246 4026
Fax: 714 246 4249